2024 - Page 501 of 2662 - Bay Street News

NASDAQ Companies - September 14, 2024

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of […]

NASDAQ Companies - September 14, 2024

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer […]

NASDAQ Companies - September 14, 2024

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically […]

NASDAQ Companies - September 14, 2024

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

– 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in […]

NASDAQ Companies - September 14, 2024

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

– Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at […]

NASDAQ Companies - September 14, 2024

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

— Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the […]

Canadian Stock Exchange News - September 13, 2024

Eco Oro Announces Change in Management Team and Board

VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) — Eco Oro Minerals Corp. (CSE:EOM) (the “Company”) announced today that Paul […]

TSX News - September 13, 2024

Prairie Provident Announces Loan Amendments and $13.2 Million Equity Rights Offering With $12 Million of Committed Participation

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) — September 13, 2024 – Prairie Provident Resources Inc. (“Prairie Provident” or the […]

TSX Venture News - September 13, 2024

Carbeeza Inc. Announces Private Placement Extension

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) — Carbeeza Inc. (“Carbeeza” or the “Company“) (TSXV:AUTO) (OTCQB: CRBAF). The TSX Venture […]

NASDAQ Companies - September 13, 2024

Upwork Confirms Receipt and Comments on Shareholder Letter

SAN FRANCISCO, Sept. 13, 2024 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses […]